<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>BMC Pharmacology - Most viewed articles</title>
		<link>http://www.biomedcentral.com/bmcpharmacol/mostviewed/</link>
		<description>Most viewed articles in last 30 days from BMC Pharmacology (ISSN 1471-2210) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/10"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/4/18"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/12"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/4"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/5"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/8"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/1"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/6"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/7"/>			    
            
				    <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2210/8/9"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/10">
            
            <title>Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives</title>
			<description>Background:
Lipid-soluble thiamine precursors have a much higher bioavailability than genuine thiamine and therefore are more suitable for therapeutic purposes. Benfotiamine (S-benzoylthiamine O-monophosphate), an amphiphilic S-acyl thiamine derivative, prevents the progression of diabetic complications, probably by increasing tissue levels of thiamine diphosphate and so enhancing transketolase activity. As the brain is particularly sensitive to thiamine deficiency, we wanted to test whether intracellular thiamine and thiamine phosphate levels are increased in the brain after oral benfotiamine administration.
Results:
Benfotiamine that is practically insoluble in water, organic solvents or oil was solubilized in 200 mM hydroxypropyl-&#946;-cyclodextrin and the mice received a single oral administration of 100 mg/kg. Though thiamine levels rapidly increased in blood and liver to reach a maximum after one or two hours, no significant increase was observed in the brain. When mice received a daily oral administration of benfotiamine for 14 days, thiamine derivatives were increased significantly in the liver but not in the brain, compared to control mice. In addition, incubation of cultured neuroblastoma cells with 10 &#956;M benfotiamine did not lead to increased intracellular thiamine levels. Moreover, in thiamine-depleted neuroblastoma cells, intracellular thiamine contents increased more rapidly after addition of thiamine to the culture medium than after addition of benfotiamine for which a lag period was observed.
Conclusion:
Our results show that, though benfotiamine strongly increases thiamine levels in blood and liver, it has no significant effect in the brain. This would explain why beneficial effects of benfotiamine have only been observed in peripheral tissues, while sulbutiamine, a lipid-soluble thiamine disulfide derivative, that increases thiamine derivatives in the brain as well as in cultured cells, acts as a central nervous system drug. We propose that benfotiamine only penetrates the cells after dephosphorylation by intestinal alkaline phosphatases. It then enters the bloodstream as S-benzoylthiamine that is converted to thiamine in erythrocytes and in the liver. Benfotiamine, an S-acyl derivative practically insoluble in organic solvents, should therefore be differentiated from truly lipid-soluble thiamine disulfide derivatives (allithiamine and the synthetic sulbutiamine and fursultiamine) with a different mechanism of absorption and different pharmacological properties.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/10</link>		
			<dc:creator>Marie-Laure Volvert, Sandrine Seyen, Marie Piette, Brigitte Evrard, Marjorie Gangolf, Jean-Christophe Plumier and Lucien Bettendorff</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:10</dc:source>
			<dc:subject>Number of accesses: 771</dc:subject>
			<dc:date>2008-06-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-10</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>10</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/4/18">
            
            <title>Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans</title>
			<description>Background:
Green tea is widely consumed in Asian countries and is becoming increasingly popular in Western countries. Epidemiologically, it has been suggested that green tea consumption prevents type 2 diabetes. The present study was aimed at providing evidence of improvement in glucose metabolism in diabetic mice and healthy humans upon green tea consumption.
Results:
Green tea promoted glucose metabolism in healthy human volunteers at 1.5 g/body in oral glucose tolerance tests. Green tea also lowered blood glucose levels in diabetic db+/db+ mice and streptozotocin-diabetic mice 2&#8211;6 h after administration at 300 mg/kg without affecting serum insulin level, whereas no effect was observed in control mice (+m/+m and normal ddY mice). The serum protein profiles of db+/db+ and +m/+m mice were analyzed for the first time by SELDI (surface-enhanced laser desorption/ionization)-TOF (time-of-flight)-MS (mass spectrometry), and then compared to investigate any effects of oral green tea administration on serum proteins. The protein profiles in db+/db+ mice showed that the spectral peak intensities at the mass/charge ratios (m/z) of 4119, 4203, 4206, 4211, 4579, 9311 and 18691 were >3 times lower, and those of 13075, 17406, 17407, 17418, 17622, 18431 and 26100 were >3 times higher than respective peak intensities in +m/+m mice. When green tea was administered to db+/db+ mice, the peak intensities were markedly decreased at m/z 11651 and 11863, and slightly decreased at m/z 4212. The peak intensities at 7495, 7595, 7808, 14983, 15614, 31204 were markedly increased after the administration.
Conclusion:
The present study provides evidence that green tea has an antidiabetic effect. Although we could not find simple reversed effect of green tea on the diabetes-induced modifications of the levels of several serum proteins, we found that the 4211 (4212) Da protein level that was decreased in the diabetic state was further decreased after green tea administration. This is the first report demonstrating that a certain serum protein may be involved in the antihyperglycemic effect of green tea. The contribution of this protein should be further studied.</description>
			<link>http://www.biomedcentral.com/1471-2210/4/18</link>		
			<dc:creator>Hiroshi Tsuneki, Mitsuyo Ishizuka, Miki Terasawa, Jin-Bin Wu, Toshiyasu Sasaoka and Ikuko Kimura</dc:creator>
			<dc:source>BMC Pharmacology 2004, 4:18</dc:source>
			<dc:subject>Number of accesses: 589</dc:subject>
			<dc:date>2004-08-26</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-4-18</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>4</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2004-08-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/12">
            
            <title>Structure-activity models of oral clearance, cytotoxicity, and LD50: a screen for promising anticancer compounds</title>
			<description>Background:
Quantitative structure-activity relationship (QSAR) models have become popular tools to help identify promising lead compounds in anticancer drug development. Few QSAR studies have investigated multitask learning, however. Multitask learning is an approach that allows distinct but related data sets to be used in training. In this paper, a suite of three QSAR models is developed to identify compounds that are likely to (a) exhibit cytotoxic behavior against cancer cells, (b) exhibit high rat LD50 values (low systemic toxicity), and (c) exhibit low to modest human oral clearance (favorable pharmacokinetic characteristics). Models were constructed using Kernel Multitask Latent Analysis (KMLA), an approach that can effectively handle a large number of correlated data features, nonlinear relationships between features and responses, and multitask learning. Multitask learning is particularly useful when the number of available training records is small relative to the number of features, as was the case with the oral clearance data.
Results:
Multitask learning modestly but significantly improved the classification precision for the oral clearance model. For the cytotoxicity model, which was constructed using a large number of records, multitask learning did not affect precision but did reduce computation time. The models developed here were used to predict activities for 115,000 natural compounds. Hundreds of natural compounds, particularly in the anthraquinone and flavonoids groups, were predicted to be cytotoxic, have high LD50 values, and have low to moderate oral clearance.
Conclusion:
Multitask learning can be useful in some QSAR models. A suite of QSAR models was constructed and used to screen a large drug library for compounds likely to be cytotoxic to multiple cancer cell lines in vitro, have low systemic toxicity in rats, and have favorable pharmacokinetic properties in humans.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/12</link>		
			<dc:creator>John C Boik and Robert A Newman</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:12</dc:source>
			<dc:subject>Number of accesses: 426</dc:subject>
			<dc:date>2008-06-13</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-12</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/4">
            
            <title>Role of sulphated polysaccharides from Sargassum Wightii in Cyclosporine A-induced oxidative liver injury in rats</title>
			<description>Background:
Seaweeds or marine algae have long been made up a key part of the Asian diet, and as an antioxidant, sulphated polysaccharides have piqued the interest of many researchers as one of the ocean's greatest treasures. The present investigation suggests the therapeutic potential of sulphated polysaccharides from marine brown algae "Sargassum wightii" in Cyclosporine A (CsA)- induced liver injury. CsA is a potent immunosuppressive agent used in the field of organ transplantations and various autoimmune disorders. However, hepatotoxicity due to CsA remains to be one of the major clinical challenges.
Methods:
The effect of sulphated polysaccharides on CsA-induced hepatotoxicity was studied in adult male albino rats of Wistar strain, and the animals were randomized into four groups with six rats in each. Group I served as vehicle control. Group II rats were given CsA at a dosage of 25 mg/kg body weight, orally for 21 days. Group III rats were given sulphated polysaccharides at a dosage of 5 mg/kg body weight, subcutaneously for 21 days. Group IV rats were given sulphated polysaccharides simultaneously along with CsA, as mentioned in Group II for 21 days.
Results:
CsA provoked hepatotoxicity was evident from the decreased activities of hepatic marker enzymes. A significant rise in the level of oxidants, along with a striking decline in both the enzymic and non-enzymic antioxidants, marks the severity of oxidative stress in CsA-induced rats. This in turn led to enhanced levels of lipid peroxidation, 8-hydroxy-2-deoxy guanosine and protein carbonyls, along with a decrease in ATPase activities and alterations in lipid profile. Histopathological changes also strongly support the above aberrations. However, concomitant treatment with sulphated polysaccharides restored the above deformities to near control and prevented the morphological alterations significantly.
Conclusion:
Thus, the present study highlights that sulphated polysaccharides can act therapeutically against CsA-induced hepatotoxicity.Key WordsCyclosporine A; hepatic markers; antioxidants; hyperlipidemia; macromolecules; sulphated polysaccharides.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/4</link>		
			<dc:creator>Anthony Josephine, Kalaiselvam Nithya, Ganapathy Amudha, Coothan Kandaswamy Veena, Sreenivasan P Preetha and Palaninathan Varalakshmi</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:4</dc:source>
			<dc:subject>Number of accesses: 403</dc:subject>
			<dc:date>2008-02-20</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-4</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/5">
            
            <title>A global view of drug-therapy interactions</title>
			<description>Background:
Network science is already making an impact on the study of complex systems and offers a promising variety of tools to understand their formation and evolution in many disparate fields from technological networks to biological systems. Even though new high-throughput technologies have rapidly been generating large amounts of genomic data, drug design has not followed the same development, and it is still complicated and expensive to develop new single-target drugs. Nevertheless, recent approaches suggest that multi-target drug design combined with a network-dependent approach and large-scale systems-oriented strategies create a promising framework to combat complex multi-genetic disorders like cancer or diabetes.
Results:
We here investigate the human network corresponding to the interactions between all US approved drugs and human therapies, defined by known relationships between drugs and their therapeutic applications. Our results show that the average paths in this drug-therapy network are shorter than three steps, indicating that distant therapies are separated by a surprisingly low number of chemical compounds. We also identify a sub-network composed by drugs with high centrality measures in the drug-therapy network, which represent the structural backbone of this system and act as hubs routing information between distant parts of the network.
Conclusion:
These findings provide for the first time a global map of the large-scale organization of all known drugs and associated therapies, bringing new insights on possible strategies for future drug development. Special attention should be given to drugs which combine the two properties of (a) having a high centrality value in the drug-therapy network and (b) acting on multiple molecular targets in the human system.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/5</link>		
			<dc:creator>Jose C Nacher and Jean-Marc Schwartz</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:5</dc:source>
			<dc:subject>Number of accesses: 388</dc:subject>
			<dc:date>2008-03-04</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-5</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/8">
            
            <title>Comparison of four different colorimetric and fluorometric cytotoxicity assays in a zebrafish liver cell line</title>
			<description>Background:
A broad spectrum of cytotoxicity assays is currently used in the fields of (eco)toxicology and pharmacology. To choose an appropriate assay, different parameters like test compounds, detection mechanism, specificity, and sensitivity have to be considered. Furthermore, tissue or cell line can influence test performance. For zebrafish (Danio rerio), as emerging model organism, cell lines are now increasingly used, but few studies examined cytotoxicity in these cell systems. Therefore, we compared four cytotoxicity assays in the zebrafish liver cell line, ZFL, to test four differently acting model compounds. The tests comprised two colorimetric assays (MTT assay using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, and the LDH assay detecting lactate dehydrogenase activity) and two fluorometric assays (alamarBlue&#174; using resazurin, and CFDA-AM based on 5-carboxyfluorescein diacetate acetoxymethyl ester). Model compounds were the pharmaceutical Tamoxifen, its metabolite 4-Hydroxy-Tamoxifen, the fungicide Flusilazole and the polycyclic aromatic hydrocarbon Benzo[a]pyrene.
Results:
All four assays performed well in the ZFL cells and led to reproducible dose-response curves for all test compounds. Effective concentrations causing 10% or 50% loss of cell viability (EC10 and EC50 values) varied by a maximum factor of 7.0 for the EC10 values and a maximum factor of 1.8 for the EC50 values. The EC values were not statistically different between the four assays, which is due to the assessed unspecific effects of the compounds. However, most often, the MTT assay and LDH assay showed the highest and lowest EC values, respectively. Nevertheless, the LDH assay showed the highest intra- and inter-assay variabilities and the lowest signal-to-noise ratios. In contrast to MTT, the other three assays have the advantage of being non-destructive, easy to handle, and less time consuming. Furthermore, AB and CFDA-AM can be combined on the same set of cells without damaging the cells, allowing later on their use for the investigation of other endpoints.
Conclusion:
We recommend the alamarBlue and CFDA-AM assays for cytotoxicity assessment in ZFL cells, which can be applied either singly or combined.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/8</link>		
			<dc:creator>Stephanie K Bopp and Teresa Lettieri</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:8</dc:source>
			<dc:subject>Number of accesses: 343</dc:subject>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-8</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/1">
            
            <title>Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25&#8211;35)-induced amnesia</title>
			<description>Background:
Accumulated evidence suggests that insulin resistance and impairments in cerebral insulin receptor signaling may contribute to age-related cognitive deficits and Alzheimer's disease. The enhancement of insulin receptor signaling is, therefore, a promising strategy for the treatment of age-related cognitive disorders. The mitochondrial respiratory chain, being involved in insulin-stimulated H2O2 production, has been identified recently as a potential target for the enhancement of insulin signaling. The aim of the present study is to examine: (1) whether a specific respiratory substrate, dicholine salt of succinic acid (CS), can enhance insulin-stimulated insulin receptor autophosphorylation in neurons, and (2) whether CS can ameliorate cognitive deficits of various origins in animal models.
Results:
In a primary culture of cerebellar granule neurons, CS significantly enhanced insulin-stimulated insulin receptor autophosphorylation. In animal models, CS significantly ameliorated cognitive deficits, when administered intraperitoneally for 7 days. In 16-month-old middle-aged C57Bl/6 mice (a model of normal aging), CS enhanced spatial learning in the Morris water maze, spontaneous locomotor activity, passive avoidance performance, and increased brain N-acetylaspartate/creatine levels, as compared to the age-matched control (saline). In rats with chronic cerebral hypoperfusion, CS enhanced spatial learning, passive avoidance performance, and increased brain N-acetylaspartate/creatine levels, as compared to control rats (saline). In rats with beta-amyloid peptide-(25&#8211;35)-induced amnesia, CS enhanced passive avoidance performance and increased activity of brain choline acetyltransferase, as compared to control rats (saline). In all used models, CS effects lasted beyond the seven-day treatment period and were found to be significant about two weeks following the treatment.
Conclusion:
The results of the present study suggest that dicholine salt of succinic acid, a novel neuronal insulin sensitizer, ameliorates cognitive deficits and neuronal dysfunctions in animal models relevant to age-related cognitive impairments, vascular dementia, and Alzheimer's disease.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/1</link>		
			<dc:creator>Zinaida I Storozheva, Andrey T Proshin, Vladimir V Sherstnev, Tatiana P Storozhevykh, Yana E Senilova, Nadezhda A Persiyantseva, Vsevolod G Pinelis, Natalia A Semenova, Elena I Zakharova and Igor A Pomytkin</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:1</dc:source>
			<dc:subject>Number of accesses: 325</dc:subject>
			<dc:date>2008-01-23</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-1</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>1</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-01-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/6">
            
            <title>Antidepressant drugs modulate growth factors in cultured cells</title>
			<description>Background:
Different classes of antidepressant drugs are used as a treatment for depression by activating the catecholinergic system. In addition, depression has been associated with decrease of growth factors, which causes insufficient axonal sprouting and reduced neuronal damage repair. In this study, antidepressant treatments are analyzed in a cell culture system, to study the modulation of growth factors.
Results:
We quantified the transcription of several growth factors in three cell lines after application of antidepressant drugs by real time polymerase chain reaction. Antidepressant drugs counteracted against phorbolester-induced deregulation of growth factors in PMA-differentiated neuronal SY5Y cells. We also found indications in a pilot experiment that magnetic stimulation could possibly modify BDNF in the cell culture system.
Conclusion:
The antidepressant effects antidepressant drugs might be explained by selective modulation of growth factors, which subsequently affects neuronal plasticity.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/6</link>		
			<dc:creator>Andreas W Henkel, Wolfgang Sperling, Andrea Rotter, Udo Reulbach, Cornelia Reichardt, Dominikus B&#246;nsch, Juan M Maler, Johannes Kornhuber and Jens Wiltfang</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:6</dc:source>
			<dc:subject>Number of accesses: 315</dc:subject>
			<dc:date>2008-03-04</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-6</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-04</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/7">
            
            <title>RU486 did not exacerbate cytokine release in mice challenged with LPS nor in db/db mice</title>
			<description>Background:
Glucocorticoids down-regulate cytokine synthesis and suppress inflammatory responses. The glucocorticoid receptor (GR) antagonist RU486 may exacerbate the inflammatory response, and concerns over this exacerbation have limited the development and clinical use of GR antagonists in the treatment of diabetes and depression. We investigated the effects of RU486 on serum cytokines in db/db mice and on lipopolysaccharide (LPS)-induced circulating TNF&#945; levels in both normal AKR mice and diet-induced obese (DIO) C57BL/6 mice.
Results:
Chronic treatment of db/db mice with RU486 dose-dependently decreased blood glucose, increased serum corticosterone and ACTH, but did not affect serum MCP-1 and IL-6 levels. LPS dose-dependently increased serum TNF&#945; in both AKR and C57BL/6 DIO mice, along with increased circulating corticosterone and ACTH. Pretreatment of the mice with RU486 dose-dependently suppressed the LPS induced increases in serum TNF&#945; and further increased serum corticosterone.
Conclusion:
RU486 at doses that were efficacious in lowering blood glucose did not exacerbate cytokine release in these three mouse models. RU486 actually suppressed the lower dose LPS-mediated TNF&#945; release, possibly due to the increased release of glucocorticoids.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/7</link>		
			<dc:creator>Baichun Yang, Ryan P Trump, Ying Shen, Judi A McNulty, Lisa G Clifton, Stephen A Stimpson, Peiyuan Lin and Greg L Pahel</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:7</dc:source>
			<dc:subject>Number of accesses: 308</dc:subject>
			<dc:date>2008-05-12</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-7</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.biomedcentral.com/1471-2210/8/9">
            
            <title>Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells</title>
			<description>Background:
The H3 histamine receptor is a Gi-coupled GPCR that has been proven to exist in different agonist-induced states, including that defined by the protean agonist proxyfan. Several GPCRs are now known to exist in different states. For some of these, antagonist affinity measurement remain constant regardless of the state of the receptor, for others e.g. the beta-adrenoceptors, the antagonist affinity measurements vary considerably depending on which agonist-dependent state is being identified. The purpose of this study was to examine the antagonist affinity measurements at the Gi-coupling human H3 receptor, paying particular attention to measurements made in the presence of full agonists, partial agonists and the proxyfan protean agonist-induced state of the receptor.
Results:
CHO cells stably expressing the human histamine H3 receptor and a CRE-SPAP reporter were used. Measurements of CRE-gene transcription and 3H-cAMP accumulation were made. A range of ligands of different agonist efficacies were determined, including some partial agonists e.g. VUF 5681. Unlike other Gi-coupled receptors, no Gs-coupled state of the receptor was detected with these ligands. Antagonist affinity measurements were constant, whether the measurements were made in the presence of a full agonist, a partial agonist or the protean agonist proxyfan.
Conclusion:
In contrast to all three subtypes of the beta-adrenoceptors, but in keeping with the traditional pharmacological dogma, antagonist affinity measurements remained constant at the human H3 receptor, including the medium-efficacy proxyfan-induced state of the receptor and the VUF5681-induced state of the receptor.</description>
			<link>http://www.biomedcentral.com/1471-2210/8/9</link>		
			<dc:creator>Jillian G Baker</dc:creator>
			<dc:source>BMC Pharmacology 2008, 8:9</dc:source>
			<dc:subject>Number of accesses: 302</dc:subject>
			<dc:date>2008-06-06</dc:date>
			<dc:identifier>doi:10.1186/1471-2210-8-9</dc:identifier>
			
			
							
					<prism:publicationName>BMC Pharmacology</prism:publicationName>
					
			
							
					<prism:issn>1471-2210</prism:issn>
					
			
							
					<prism:volume>8</prism:volume>
					
			
							
					<prism:startingPage>9</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-06</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
